Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IXEMPRA ® safely and effectively. See full prescribing information for IXEMPRA ®. IXEMPRA ® Kit (ixabepilone) for Injection, for intravenous infusion only Initial U.S. Approval: 2007
Medication labelWhy this: Advisory · dailymed-prescription
IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14)]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14)].
- generic_name
- ixabepilone
- brand_name
- diluent
- product_names
- ixabepilone, diluent
- ndc
- 70020-1910, 70020-1910-1, 70020-1911, 70020-1911-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en